Lexicon Pharma (LXRX) Misses Q2 EPS by 4c, Revenues Beat

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 11/5/2026

1. HUBS
2. FIS
3. BROS
4. EXPE
5. ARM
6. QCOM
7. DDOG
8. CPAY
9. CHYM
10. W

Go back to Lexicon Pharma (LXRX) Misses Q2 EPS by 4c, Revenues Beat

Lexicon Pharma (LXRX) to Resume Trading at 7:45 a.m.

July 30, 2020 7:42 AM EDT

Lexicon Pharma (NASDAQ: LXRX) to Resume Trading at 7:45 a.m.

... More

Lexicon Pharma (LXRX) Realigns Business Around Research and Development Assets, with Focus on Phase 2 LX9211 Neuropathic Pain Program

July 30, 2020 7:42 AM EDT

Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) announced today that it is realigning its business around its research and development assets, with a focus on its LX9211 neuropathic pain program, now in Phase 2 clinical development. In that regard:

Initiation of Phase 2 Clinical Development of LX9211. Lexicon has initiated patient screening in RELIEF-DPN-1, a Phase 2 randomized, placebo-controlled,... More

Lexicon Pharma (LXRX) Announces Sale of XERMELO for $159 Million

July 30, 2020 7:11 AM EDT

Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) and TerSera Therapeutics LLC announced today that they have entered into an asset purchase and sale agreement for the sale to TerSera of Lexicons rights, title and interest in XERMELO® (telotristat ethyl).

Pursuant to the terms of the agreement, TerSera will pay Lexicon approximately $159 million in cash at closing, which includes a $155 million upfront... More

Lexicon Pharma (LXRX) Halted, News Pending

July 30, 2020 6:58 AM EDT

Lexicon Pharma (NASDAQ: LXRX) Halted, News Pending

... More